Article Abstract

PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Authors: Alfredo Addeo, Giuseppe Luigi Banna


We have read with great interest our Colleagues’ point of view suggesting that immunotherapy should not be integrated into the treatment of oncogene-driven non-small cell lung cancers (NSCLCs) based on currently available evidence. However, we would like to mention three points to challenge their recommendation.